The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients
However, in the combination group, the trend of reduced locomotor activity on days 7 and 14 and increased locomotor activity on day 21 was observed as compared to their treatment alone
Host defense peptides and their antimicrobial-immunomodulatory duality
Another systematic review and comprehensive analysis indicated that antidepressants vary in their ability to enter amniotic fluid, cord blood, and breast milk, with citalopram having the highest permeability (mean permeability of active molecules: 2.03, range: 0.356.97) and fluoxetine having the lowest permeability (mean permeability of active molecules: 0.11, range: 0.020.20) (Figure 2)
